As of 2024-12-15, the EV/EBITDA ratio of Silence Therapeutics PLC (SLN.L) is -6.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SLN.L's latest enterprise value is 427.08 mil GBP. SLN.L's TTM EBITDA according to its financial statements is -70.13 mil GBP. Dividing these 2 quantities gives us the above SLN.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 14.4x | 13.2x |
| Forward P/E multiples | 15.8x - 17.6x | 16.7x |
| Fair Price | (1,113.66) - (1,008.22) | (1,047.76) |
| Upside | -308.2% - -288.5% | -295.8% |
| Date | EV/EBITDA |